{
    "clinical_study": {
        "@rank": "55492", 
        "arm_group": [
            {
                "arm_group_label": "DbXell", 
                "arm_group_type": "Experimental", 
                "description": "Drug: DbXell three times daily for 12 weeks and then switching to Placebo of DbXell  for 12 additional months Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Drug: Placebo of DbXell Placebo of DbXell  three times daily for 12 weeks and then switching to DbXell  for 12 additional weeks Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 2-arm, single-blind, crossover, placebo-controlled clinical study, with 24 weeks\n      of therapy to evaluate the efficacy and safety of DbXell  in improving metabolic control in\n      patients with Type 2 Diabetes that is mildly uncontrolled, defined as HbA1c above target but\n      less than 8.0% on their current conventional therapy."
        }, 
        "brief_title": "Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus", 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects with age of 18-70 years Established type 2 diabetes mellitus\n             as defined by the American Diabetes Association, but of duration less than 10 years.\n\n          -  Suboptimal glycemic control as judged by HbA1c over target but not more than\n             8.0%.Current medication of not more than 2 oral hypoglycemic agents. No current or\n             past insulin or GLP1 therapy.\n\n          -  FPG \u2264 180 mg/dL\n\n          -  Hemoglobin level of \u2265 10.0 g/dL\n\n          -  Serum ALT \u2264 2.5 times upper limit of normal\n\n          -  Serum creatinine < 1.5 times upper limit of normal\n\n        Exclusion Criteria:\n\n          -  Female of childbearing potential\n\n          -  Subjects with symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or other symptomatic ischemic arterial diseases necessitating medical\n             treatment\n\n          -  Uncontrolled hypertension (SBP > 160 mmHg and/or DBP > 100 mmHg)\n\n          -  History of renal and/or liver disease\n\n          -  History of or the presence of any clinical evidence of malignancies\n\n          -  Presence of exacerbation of chronic illnesses, severe and acute infections,\n             complicated infections\n\n          -  Current treatment with systemic corticosteroids or herbal (alternative) medicines\n\n          -  Participation in any other intervention trial within 30 days prior to Screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123732", 
            "org_study_id": "DbXell1234"
        }, 
        "intervention": [
            {
                "arm_group_label": "DbXell", 
                "intervention_name": "DbXell", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes", 
            "Diabetes Mellitus", 
            "Herbal", 
            "food supplement"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "contact": {
                "email": "mniven@laniado.org.il", 
                "last_name": "Mark J Niven, MD", 
                "phone": "+972-9-860-9325"
            }, 
            "contact_backup": {
                "email": "oshmulevitz@laniado.org.il", 
                "last_name": "Odelia Shmulevitz, Mrs.", 
                "phone": "+972-9-892-5248"
            }, 
            "facility": {
                "address": {
                    "city": "Netanya", 
                    "country": "Israel", 
                    "zip": "42150"
                }, 
                "name": "Laniado Hospital, Diabetes Unit"
            }, 
            "investigator": {
                "last_name": "Mark J Niven, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Laniado Hospital", 
            "last_name": "Mark J Niven, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1C concentrations and fasting glucose levels", 
            "safety_issue": "Yes", 
            "time_frame": "6 months from last patient in"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123732"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Laniado Hospital", 
            "investigator_full_name": "Laniado Hospital", 
            "investigator_title": "Dr Mark J NIVEN Director of Endocrine and Diabetes Unit", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Laniado Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "K.G.S Research & Entrepreneurship, Israel", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Laniado Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}